SUMMARY The therapeutic efficacy of orally administered branched-chain amino acids in patients with liver cirrhosis and chronic encephalopathy was examined in a double-blind, randomised crossover study. Seven patients with manifest hepatic cirrhosis and encephalopathy of six months' duration or longer ingested 30 g branched-chain amino acids or placebo during two 14-day periods. Psychometric tests and electroencephalograms were used to evaluate cerebral function. Neither clinical observations nor psychometric testing or electroencephalogram indicated a significant difference in the patients' response to branched-chain amino acids as compared with placebo. In four patients given branched-chain amino acids for longer periods (five to 22 weeks), psychometric tests also remained unchanged. The plasma concentrations of these acids after oral intake increased significantly, demonstrating adequate absorption. Basal plasma amino acid concentrations were unchanged, however, after branched-chain amino acid therapy. No side-effects were seen, which indicates that these amino acids are well tolerated as an extra protein supply in patients with chronic hepatic encephalopathy. As compared with placebo, however, no effect of branched-chain amino acids on the encephalopathy could be detected.
It has recently been suggested that administration of branched-chain amino acids to patients with liver cirrhosis and encephalopathy may improve cerebral function, thereby offering a new therapeutic approach in this disorder.l`The biochemical basis for this suggestion is related to the characeristic plasma amino acid pattern found in patients with severe liver cirrhosis: high levels of aromatic amino acids and reduced concentrations of the three branched-chain amino acids, leucine, isoleucine, and valine. 4 5 It has been postulated that these alterations, together with an augmented permeability of the blood-brain barrier for neutral amino acids,6 result in an increased influx of aromatic amino acids to the brain, thereby eliciting an imbalance in the brain's synthesis of neurotransmitters, particularly serotonin and noradrenaline. 7 8 This may result in an accumulation of 'false' neurotransmitters such as octopamine,2 9 which in turn may be responsible for the cerebral dysfunction associated with hepatic encephalopathy.
Administration of branched-chain amino acids to such patients should increase their concentration in the blood and uptake in the brain, thereby reducing the influx of aromatic amino acids to the brain and normalising neurotransmitter synthesis. Indeed, intravenous administration of these amino acids to patients with hepatic cirrhosis is reported to lower whole blood concentrations and reduce brain uptake of aromatic amino acids.5 Recently, it was proposed that ingestion of a diet enriched with branched-chain amino acids may improve chronic hepatic encephalopathy.3 This report, however, involved only one patient and no controlled clinical trials with these amino acids have yet been reported concerning cerebral function in patients with hepatic encephalopathy. Therefore, the present study was undertaken to evaluate the efficacy of oral treatment with branched-chain amino acids in patients with cirrhosis and chronic hepatic encephalopathy. admitted to the study. All had clinical and laboratory evidence of severe liver disease and histologically verified liver cirrhosis of varying aetiology (Table 1) . One patient (no. 4) had a surgical portacaval shunt. All patients had been seen regularly at the outpatient clinic and had a history of clinically overt stable chronic hepatic encephalopathy (grade I-IT in a IV-graded scale, according to Conn 0) for six months or more (Table 1) 
Results
Before the trial the patients exhibited varying degrees of difficulty in concentration, abnormal sleep pattern, tiredness, irritability, and personality changes. During the first treatment period the degree of encephalopathy improved in five of the patients (three given branched-chain amino acids and two placebo) -two from grade II to I, three from grade I to 0, while two were unchanged (grade I). In the second treatment period two patients deteriorated clinically: one patient treated with branched-chain amino acids had a return of difficult concentration, sleep disturbance, and irritability (grade 0 to I), and one patient receiving placebo shifted from grade I to III during the first week (of the second period) and subsequently reverted to grade I within the observation period. The clinical status of the other patients was unchanged. During long-term treatment with branched-chain amino acids one patient deteriorated (grade I to III) and subsequently died in hepatorenal failure after five weeks; the clinical status of the other patient remained unchanged.
The results from the psychometric testing before the therapeutic trial and after the two treatment modalities (branched-chain amino acids and placebo) are presented in Before the trial four patients showed a definitely abnormal EEG, two of which were of characteristic pre-coma appearance. During branched-chain amino acids administration the EEG improved in two patients, deteriorated in one, and showed an unchanged pattern in four. When placebo was given improvements were seen in three patients and deterioration in one. Two patients with normal EEGs showed unchanged patterns during both treatment periods. As expected, the plasma amino acid concentrations in the basal, postabsorptive state showed an abnormal pattern: low levels of branched-chain amino acids and raised concentrations of tyrosine, phenylalanine, and methionine (Table 3) . No consistent changes were subsequently seen in the basal amino acid levels during either the two week crossover study or after prolonged administration of branched-chain amino acids ( Table 3) .
The concentrations of plasma amino acids immediately after oral ingestion of 7.5 g of branched-chain amino acids are shown in the Figure. All three branched-chain amino acids increased by a maximum of two to eight fold and returned to baseline by two to three hours. In contrast there was a consistant fall in the levels of tyrosine (-35%), phenylalanine (-55%), and methionine (-60%). These concentrations remained depressed for at least three hours after branched-chain amino acids ingestion in all five patients studied.
No significant changes were seen in the serum concentrations of albumin, creatinine, electrolytes, or liver enzymes during the crossover study.
Discussion
The present trial was designed to study the effect of branched-chain amino acids on cerebral function in patients with liver cirrhosis and chronic encephalopathy. Thus, 30 g of branched-chain amino acids was added to the patients' regular diet. As is evident from A pertinent question is whether the administered amino acids were, in fact, absorbed. Serial measurements within three hours after ingestion of one quarter of the daily branched-chain amino acid dosage revealed a substantial rise in leucine, valine, and isoleucine concentrations as well as a marked diminution in the levels of tyrosine, phenylalanine, and methionine. We may thus conclude that ingestion of these amino acids was accompanied by their rapid gastrointestinal absorption and raised plasma levels, as well as a fall in the levels of aromatic amino acids similar to that reported to accompany intravenous branched-chain amino acid infusion.S
The study period in the present trial was set at 14 days on the assumption that this would be sufficient to reveal any positive effects of branched-chain amino acids ingestion. For patients with acute hepatic coma, improvement is said to occur within the first one or two days of this treatment.' Patients with longstanding encephalopathy, however, may require a longer period of treatment before any improvement can be seen. In the patient reported by Freund et a13 the first signs of improved cerebral function were seen after one week. In order to examine the possibility of a long-term effect, six of the present patients received branched-chain amino acids, 30 g daily, for five to 22 weeks after the initial trial. No further improvement was noted, however, either in the patients' symptoms or in the psychometric test results. Thus, neither brief nor prolonged periods of branched-chain amino acids treatment appear capable of influencing the encephalopathy in these patients. It should be noted that, while administration of branched-chain amino acids raised postprandial plasma levels of these amino acids ( Figure) , the basal concentrations of branched-chain amino acids and aromatic amino acids remained unchanged (Table 3) . This was true after either two weeks or more prolonged (five to 22 weeks) treatment with these amino acids. Given the rapid decline in plasma branched-chain amino acids which occurs after an oral load (Figure) , one cannot expect that an oral regimen will restore normal basal plasma amino acid concentrations. The improvement in patients with hepatic coma observed after intravenous branchedchain amino acids' may thus be a consequence of continuous administration of amino acids and normalisation of the plasma amino acid profile throughout the day.
The experimental design used in the current study involved an increased amino acid intake of 30 g/day during this treatment. Although no comparable increase in mixed protein administration was given during the placebo period, the possibility cannot be excluded that branched-chain amino acids were in fact less toxic (with respect to psychometrics or EEG) than an isonitrogenous load of protein. In the present study utilisation of these amino acids was not examined, but, as no side-effects were observed, branched-chain amino acids might conceivably constitute a means of increasing nitrogen intake in cirrhotic patients without causing a deterioration in encephalopathy. On the other hand, the data clearly indicate that, compared with a nitrogen-free placebo, the branched-chain amino acids regimen fails to improve cerebral function.
The suggestion that 'false' neurotransmitters may be of pathogenetic importance for hepatic encephalopathy has received much attention recently. Findings concerning brain concentrations of catecholamines and octopamine, however, show no significant differences between patients with hepatic encephalopathy and control patients.18 Moreover, preliminary results from a controlled study involving intravenous infusion of branched-chain amino acids in patients with hepatic coma demonstrate no positive influence on consciousness when compared with ordinary amino acid solutions. '9 The results from the present study are in accordance with these findings -no tendency to improvement after oral administration of branched-chain amino acids.
ADDEN DUM
The findings in a recent study by McGhee et aP2" in which cirrhotic patients ingested a branched-chain amino acid enriched diet support the conclusion of the present report that these amino acids fail to exert a beneficial effect on hepatic encephalopathy. This study was 
